Why Alpha Beats Beta: New Lab Science on How Targeted Radiation Kills Prostate Cancer

Differential Radiobiological Effects of Αlpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival - International Journal of Radiation Oncology, Biology, Physics

How to Make It Work at Lower Doses

An IPCSG Newsletter feature on the radiobiology behind Pluvicto, Actinium-225, and the next wave of radioligand therapy. The author is a participant in a current Actinium 225 trial at UCSD Health Moores Cancer Center after having failed on Pluvicto.

Bottom Line Up Front

Targeted radionuclide therapy (TRT) — the class of treatment that includes the FDA-approved drug Pluvicto — delivers radiation directly to prostate cancer cells by riding on a molecule that locks onto PSMA, a protein studded on the surface of most prostate tumors. Two "payload" radioisotopes dominate the field: lutetium-177 (a beta-minus emitter, already approved) and actinium-225 (an alpha emitter, still investigational). A newly reported laboratory study from the German Cancer Research Center (DKFZ) in Heidelberg pins down why alpha particles hit so much harder: they produce complex, hard-to-repair DNA damage and achieve the same effect as beta radiation at roughly 1% of the activity (100-fold less). The study also showed that pairing TRT with a drug that blocks the cell's DNA-repair machinery (a DNA-PK inhibitor) let researchers cut the required actinium dose 64-fold while keeping the same cancer-killing punch — and even dented the toughest, treatment-resistant cell line.

Why it matters to you: Actinium-225 is in critically short supply and can cause dry-mouth and marrow toxicity at higher doses. Anything that makes each precious dose go further — better targeting, smarter drug combinations — could widen access, lower side effects, and rescue patients whose cancer has stopped responding. This is bench science, not a treatment you can ask for today, but it maps directly onto human trials now underway.

The three-part promise of "smart" radiation

A good cancer therapy has to thread three needles at once: hit the tumor precisely, hit it hard enough to matter, and spare healthy tissue. Radioligand therapy tries to do all three by strapping a radioactive atom to a targeting molecule that seeks out PSMA-positive prostate cancer cells wherever they hide — in bone, lymph nodes, or organs. The radiation is then delivered from the inside, cell by cell.

The approach graduated from promise to practice when the FDA approved [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto) in March 2022 for men with metastatic castration-resistant prostate cancer (mCRPC) who had already been through hormone-blocking therapy and chemotherapy. The pivotal VISION trial had shown Pluvicto extended overall survival to a median of about 15.3 months versus 11.3 months for standard care, and slowed radiographic progression substantially. In March 2025, the FDA expanded the label so appropriate men can now receive Pluvicto before chemotherapy, based on the PSMAfore trial — a genuine shift in the treatment sequence. Novartis has since reported that its PSMAddition trial pushed the drug even earlier, into hormone-sensitive disease, meeting its primary endpoint in 2026.

The catch that drives the science: Even with these wins, roughly 30–40% of patients either fail to respond to PSMA-targeted radiation or develop resistance over the course of treatment. When researchers look at who resists, they repeatedly find tumors carrying mutations in DNA damage-repair genes. That is the thread this new study pulls on.

What the DKFZ team actually did

The Heidelberg group (corresponding author Ruth Winter) ran a carefully controlled, apples-to-apples comparison — something surprisingly rare, because most labs can only get their hands on one isotope at a time. They exposed three prostate cancer cell lines to PSMA-targeted actinium-225 or lutetium-177, using external X-ray beams as a reference yardstick:

• LNCaP and C4-2 — PSMA-positive lines that internalize the targeting molecule.
• PC-3 — a PSMA-negative, notoriously radiation-resistant line used as the hard test case.

They then measured DNA double-strand breaks — the lethal kind of DNA damage — by lighting up a marker called γH2AX under the microscope, and tracked how those breaks were repaired (or not) over 72 hours. Finally, they added a DNA-PK inhibitor to see whether sabotaging the repair crew made the radiation more deadly.

Finding 1: Alpha does with 1 unit what beta needs 100 units to do

Across both PSMA-positive lines, actinium-225 produced the same number of DNA break "foci" as lutetium-177 while using roughly 100-fold less radioactivity. When the researchers looked at long-term cell survival over eight days, the gap grew even wider — on the order of 500-fold. In the most striking single comparison, the lowest actinium dose tested matched the highest lutetium dose for killing power, a 32,000-fold difference in raw activity for an equivalent effect.

The alpha "hits" were also visibly different: larger, brighter damage spots reflecting the dense, tangled, hard-to-fix lesions that high-energy alpha particles carve as they plow a short, brutal track through the nucleus. Beta particles and X-rays left smaller, simpler, more repairable breaks.

Finding 2: For alpha, getting inside the cell is everything

Here the physics becomes practical. An alpha particle travels only about 50–100 micrometers — a few cell diameters — before stopping. A beta particle travels 1–2 millimeters, crossing many cells (so-called "crossfire"). The study confirmed the consequence:

• Actinium (alpha): when the drug was pulled inside the cell by PSMA, DNA damage rose sharply (about 1.3-fold over non-internalized). Internalization is essential.
• Lutetium (beta): whether it got inside or just sat on the membrane barely mattered — its longer reach did the work either way.

Design lesson for future drugs: Alpha-emitter therapies need targeting molecules that are quickly internalized and held tightly inside, and they depend on uniform PSMA expression across the tumor. Beta emitters are more forgiving of patchy, heterogeneous targets because their crossfire reaches neighbors that were missed. Different isotopes, genuinely different design rules.

Finding 3: Alpha damage stays broken

After X-ray or lutetium exposure, the DNA-break signal faded toward normal within a day or two — the cells repaired themselves. After actinium, the damage signal stayed elevated across the full 72-hour window, running two- to three-fold above baseline. That persistence — damage the cell simply cannot fix — is the mechanistic reason alpha therapy overwhelms cancer cells so much more effectively, including the resistant PC-3 line.

Finding 4: Block the repair crew, and you need far less radiation

Because TRT kills mainly by breaking DNA, the team reasoned that jamming the cell's repair machinery should amplify the effect. They used Nedisertib (also known as peposertib or M3814), an inhibitor of DNA-PK — a master enzyme in the "non-homologous end joining" repair pathway. The results in the C4-2 line:

Isotope	Dose reduction possible when combined with DNA-PK inhibitor	Effect in resistant PC-3 line
Actinium-225 (alpha)	64-fold lower activity for equal effect	Viability driven below 50% (to ~34%) with combination
Lutetium-177 (beta)	4-fold lower activity for equal effect	Combination markedly weaker (~81% viability)

The headline: DNA-PK inhibition supercharged both isotopes, but the payoff was dramatically larger for alpha. That 64-fold dose reduction is not a rounding detail — it speaks directly to actinium's two biggest real-world problems, scarcity and toxicity.

Why this laboratory story connects to real trials

This is preclinical work — cells in dishes, not patients — and the authors are candid that gold-standard "clonogenic survival" assays and animal studies are the necessary next steps. But the questions it answers are exactly the ones the clinical field is wrestling with right now:

Actinium-225 is moving fast in humans

Multiple first-in-human alpha-therapy trials reported encouraging early results through 2026. Bayer's PAnTHA study of ²²⁵Ac-PSMA-Trillium reported a 62% PSA-50 response rate overall (83% at the higher dose level) with acceptable safety in heavily pretreated men. Full-Life Technologies' 225Ac-FL-020 (ProTACT trial) and Blue Earth Therapeutics' 225Ac-rhPSMA-10.1 (first patient dosed July 2026) are among a growing list. A 2025 systematic review concluded PSMA-targeted alpha therapy shows promising efficacy with an acceptable safety profile.

The dry-mouth problem is real — and dose-driven

Actinium's decay throws off a daughter isotope, francium-221, that concentrates in the salivary glands, which helps explain the xerostomia (dry mouth) seen after actinium therapy. Anything that lets doctors use less actinium per treatment — like the DNA-PK combination in this study — could ease that burden.

Supply is the binding constraint

Actinium-225 is genuinely scarce; global clinical output is still measured in a small number of curies per year, and at least one company paused a late-stage trial in 2024 over shortage. In March 2026, TerraPower Isotopes announced a $450 million actinium-225 plant in Philadelphia projected to raise capacity roughly twentyfold when it opens around 2029. Until that capacity arrives, dose-sparing strategies are not just elegant — they are how more men get treated.

Combination therapy is a clinical frontier

Trials are actively pairing radioligand therapy with DNA-repair-blocking drugs. The related LuPARP trial combined Pluvicto with the PARP inhibitor olaparib; DNA-PK inhibitors like AZD7648 and BAY-8400 have been paired with radionuclides in other models. A recurring lesson from 2026 conference discussions: timing matters enormously — full repair blockade early, with intermittent scheduling to control overlapping toxicity. This study's clean demonstration that DNA-PK inhibition amplifies alpha therapy most of all adds mechanistic weight to that clinical direction.

Plain-language glossary

PSMA — prostate-specific membrane antigen; a protein on most prostate cancer cells that targeting drugs latch onto.
Alpha vs. beta-minus emitter — alpha particles (e.g., actinium-225) are heavy, high-energy, and travel only a few cell widths; beta particles (e.g., lutetium-177) are lighter, lower-energy, and travel farther.
Double-strand break — the most lethal form of DNA damage; both strands of the DNA ladder are severed.
DNA-PK inhibitor — a drug that blocks a key DNA-repair enzyme so radiation damage can't be fixed.
mCRPC — metastatic castration-resistant prostate cancer; disease that has spread and is progressing despite hormone therapy.
Internalization — the process of a targeting drug being pulled inside the cell rather than staying on its surface.

What to take away

The engineering logic here is clean. Alpha radiation is a short-range sledgehammer that makes damage cells can't repair; beta radiation is a longer-range tool that's more forgiving of imperfect targeting but easier for cells to survive. Knowing which is which tells drug designers what to optimize — tight internalization for alpha, strong sustained binding for beta — and tells clinicians that blocking DNA repair can stretch a scarce, toxic-at-high-dose isotope much further. None of it is a prescription you can fill today, but all of it is being tested in men right now. For patients who have exhausted current options, that pipeline is worth watching closely, and worth asking your oncologist about clinical-trial eligibility.

Verified sources

1. Winter R, et al. "Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival." International Journal of Radiation Oncology, Biology, Physics (Red Journal), 2026. https://www.redjournal.org (source article provided).
2. U.S. FDA. "FDA expands Pluvicto's metastatic castration-resistant prostate cancer indication." March 28, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication
3. Sartor AO, Castellano D, Herrmann K, et al. "Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive mCRPC (PSMAfore)." Lancet. 2024;404(10459):1227–1239. doi:10.1016/S0140-6736(24)01653-2.
4. Urology Times. "FDA approves expanded label for 177Lu-PSMA-617 in mCRPC." July 2026. https://www.urologytimes.com/view/fda-approves-expanded-label-for-177lu-psma-617-in-mcrpc
5. Urology Times. "Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC (PSMAddition)." July 2026. https://www.urologytimes.com/view/adding-lutetium-177lu-vipivotide-tetraxetan-to-soc-improves-rpfs-in-mhspc
6. Kratochwil C, Giesel FL, Heussel CP, et al. "Patients Resistant Against PSMA-Targeting Alpha-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes." J Nucl Med. 2020;61(5):683–688.
7. Ninatti G, Scilipoti P, Pini C, et al. "Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer — a systematic review and meta-analysis." Theranostics. 2025. doi:10.7150/thno.106574. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905128/
8. Hotte SJ, Jayaram A, Artigas C, et al. "First-in-human 225Ac-PSMA-Trillium (BAY 3563254) in mCRPC: dose-escalation results of the phase 1 PAnTHA study." J Clin Oncol. 2026;44(7_suppl):19. https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.19
9. Targeted Oncology. "Actinium-225 Demonstrates Safety and Responses in mCRPC." June 22, 2026. https://www.targetedonc.com/view/actinium-225-demonstrates-safety-and-responses-in-mcrpc
10. Urology Times. "Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC (Blue Earth Therapeutics)." July 2026. https://www.urologytimes.com/view/trial-launches-of-actinium-225ac-rhpsma-10-1-injection-in-mcrpc
11. UroToday / ASCO GU 2026. "ProTACT: First-in-Human Phase 1 of 225Ac-FL-020 (Full-Life Technologies) in mCRPC." https://www.urotoday.com/video-lectures/asco-gu-2026/video/5480-protact-trial...
12. Zitzmann-Kolbe S, Remde Y, Moen I, et al. "Biodistribution of free Francium-221 and Bismuth-213 in tumour-bearing SCID mice." Eur J Nucl Med Mol Imaging. 2025;53(1):633–646.
13. TerraPower Isotopes / OncoDaily. "TerraPower Isotopes Invests $450M in Actinium-225 Production Facility." March 17, 2026. https://oncodaily.com/technology/actinium-225471718
14. BioSpace. "Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand." February 2026. https://www.biospace.com/business/radiopharma-sector-races-to-secure-actinium-225-supply-as-pipelines-expand
15. U.S. DOE National Isotope Development Center. "Multiple Production Methods Underway to Provide Actinium-225." https://www.isotopes.gov/information/actinium-225
16. UroToday / UCSF-UCLA PSMA Conference. "PSMA and Beyond 2026: Lessons Learned from Radioligand Combination Therapies (incl. LuPARP)." March 2026. https://www.urotoday.com/conference-highlights/2026-ucsf-ucla-psma-conference/167787...
17. Graf F, Fahrer J, Maus S, et al. "DNA Double Strand Breaks as Predictor of Efficacy of Ac-225 and Lu-177 for Somatostatin Receptor Targeted Radiotherapy." PLoS One. 2014;9(2):e88239.

This article is provided by the Informed Prostate Cancer Support Group for educational purposes only and is not medical advice. The DKFZ study described here is laboratory (preclinical) research; actinium-225 PSMA therapy and DNA-PK inhibitor combinations remain investigational and are not FDA-approved for prostate cancer. Pluvicto (lutetium-177 PSMA-617) is FDA-approved for specific mCRPC indications. Always discuss treatment options and clinical-trial eligibility with your own oncology team.